IVERIC bio's Rally
IVERIC Bio (ISEE) announced that the U.S. (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP), also known as Zimura®.
Zimura is a novel investigational complement C5 inhibitor aimed at treating geographic atrophy (GA) secondary to Age-Related . . .
This content is for paid subscribers.
Today’s Highlights
November 18, 2022
